Kathryn Guarini Sells 400 Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) Stock

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Director Kathryn Guarini sold 400 shares of the stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $800.00, for a total transaction of $320,000.00. Following the transaction, the director owned 603 shares in the company, valued at approximately $482,400. The trade was a 39.88% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Regeneron Pharmaceuticals Trading Up 1.0%

NASDAQ:REGN opened at $805.97 on Friday. The firm has a 50-day simple moving average of $672.43 and a 200-day simple moving average of $713.71. Regeneron Pharmaceuticals, Inc. has a one year low of $541.00 and a one year high of $821.11. The firm has a market cap of $82.98 billion, a P/E ratio of 19.92, a P/E/G ratio of 1.36 and a beta of 0.22. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.78 and a current ratio of 3.34.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $14.29 EPS for the quarter, topping analysts’ consensus estimates of $10.16 by $4.13. The company had revenue of $4.29 billion during the quarter, compared to the consensus estimate of $3.82 billion. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. Regeneron Pharmaceuticals’s revenue for the quarter was up 16.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $12.81 earnings per share. Equities analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 44.25 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, August 31st. Stockholders of record on Tuesday, August 18th will be given a $0.94 dividend. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. The ex-dividend date of this dividend is Tuesday, August 18th. Regeneron Pharmaceuticals’s payout ratio is presently 9.29%.

Institutional Trading of Regeneron Pharmaceuticals

A number of institutional investors have recently bought and sold shares of REGN. WPG Advisers LLC increased its stake in Regeneron Pharmaceuticals by 312.5% during the 4th quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 25 shares in the last quarter. SHP Wealth Management acquired a new position in shares of Regeneron Pharmaceuticals in the 4th quarter valued at $26,000. Western Wealth Management LLC purchased a new position in Regeneron Pharmaceuticals in the 1st quarter worth $26,000. Titan Wealth CI Ltd purchased a new position in Regeneron Pharmaceuticals in the 4th quarter worth $29,000. Finally, Mowery & Schoenfeld Wealth Management LLC acquired a new stake in Regeneron Pharmaceuticals during the 2nd quarter worth about $29,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Regeneron agreed to collaborate with Parabilis Medicines on antibody-Helicon conjugates, providing Parabilis with $125 million in upfront consideration and an equity investment. Regeneron could also receive as much as $2.2 billion in milestone payments, plus tiered royalties, if the programs succeed. The deal expands Regeneron’s drug-development capabilities and adds potential long-term pipeline value. Parabilis Medicines Reports Second Quarter 2026 Financial Results and Provides Business Updates
• Positive Sentiment: Recent fundamentals remain supportive: Regeneron’s latest quarterly results exceeded analyst expectations, with earnings per share of $14.29 versus a $10.16 consensus and revenue of $4.29 billion versus estimates of $3.82 billion. Revenue increased 16.7% year over year, reinforcing investor confidence in the business and its ability to fund pipeline development.
• Neutral Sentiment: Directors Huda Y. Zoghbi and Kathryn Guarini sold $640,000 and $320,000 of stock, respectively, at approximately $800 per share. Both transactions were executed under pre-arranged Rule 10b5-1 plans, which reduces their usefulness as indicators of current management sentiment. Director Sale Filing
• Negative Sentiment: Multiple law firms publicized a securities class action tied to allegations that Regeneron misled investors about the prospects of its Phase 3 fianlimab-Libtayo trial for advanced melanoma. The trial’s failed primary endpoint reportedly erased about $11 billion in market value and may increase concerns about litigation expenses, disclosure practices and the oncology pipeline. Investors seeking lead-plaintiff status face a September 14, 2026 deadline. Regeneron Class Action Lawsuit Notice

Analysts Set New Price Targets

REGN has been the subject of a number of recent research reports. Benchmark upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $185.00 target price for the company in a report on Tuesday, July 7th. Weiss Ratings reiterated a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research note on Wednesday, June 24th. Guggenheim increased their target price on shares of Regeneron Pharmaceuticals from $1,000.00 to $1,030.00 and gave the company a “buy” rating in a research report on Monday, August 3rd. HSBC lowered their target price on shares of Regeneron Pharmaceuticals from $990.00 to $880.00 and set a “buy” rating for the company in a research note on Monday, July 6th. Finally, BMO Capital Markets cut their price target on shares of Regeneron Pharmaceuticals from $900.00 to $730.00 and set an “outperform” rating on the stock in a report on Monday, May 18th. Sixteen investment analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the stock. According to MarketBeat.com, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $793.74.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.